Indirect spectrophotometric detection by reversed-phase liquid chromatography. Application in drug analysis

By inclusion of a high U.V. or visible-absorbing component to the mobile phase of a RP-HPLC system, it is possible, after they were separated by chromatography, to detect indirectly and to quantify analytes which do not themselves absorb at the detection wavelength. The principles of this "indirect detection", as well as the parameters which can influence it were studied, and the method was applied to the qualitative and quantitative determination of a lot of compounds used as active substances or as technological adjuvants in drugs.     

The Patient Reported Outcomes as a Clinical Tool (PROACT) Pilot Study: What Can be Gained by Sharing Computerized Patient-Reported Mental Health and Substance Use Symptoms with Providers in HIV Care?

AIDS and Behavior - Substance use and mental health (SU/MH) disorders are insufficiently recognized in HIV care. We examined whether conveying SU/MH screening results to patients and providers...     

Care and outcome of 55 children born to HIV seropositive mothers

We report our experience with vertically transmitted HIV infection in infants. Fifty-five children were prospectively followed for a period of 3 years. The neonatal diagnosis of HIV infection is not always possible and doubts about contamination may create familial anxiety which requires support by a multidisciplinary structure. Long-term prognosis is difficult to predict and it depends on the severity of the immune deficiency, the early onset of neurologic disease and the frequency of opportunistic infections.     

Postprandial variations in serum bile acid levels in humans free of hepatic or intestinal diseases (author's transl)

The levels of unsulfated, free or conjugated cholic, deoxycholic and chenodeoxycholic acids were measured using gas chromatography in 39 humans free of hepatic or intestinal diseases before and 10, 60, 120 and 180 min after ingestion of a standard meal. The probable maximal levels were determined with an error risk lower than 0.05. In fasting subjects, the observed values are comparable with those obtained by other authors working with gas chromatography or radioimmunoassay. Meal ingestion does not influence in the same way the serum levels of the various bile acids: the chemodeoxycholic serum level rose significantly in all cases whereas cholic and deoxycholic serum levels rose only in two-thirds of observed subjects; 60 and 120 min after the meal for chenodeoxycholic acid, and only 60 min after the meal for cholic acid, the mean values are significantly higher than the fasting ones; 120 min after the meal, the chenodeoxycholic and total bile acid probable maximal levels (respectively 7.4 and 10.3 micrometer) are twice the fasting ones. The cholic to chenodeoxycholic serum level ratio is nearly always lower than 1 but may reach 3. On the basis of these results, the validity and efficacy of the exploration tests based on serum bile acid level determinations are discussed.     

Tazarotene-induced gene 3 is suppressed in basal cell carcinomas and reversed in vivo by tazarotene application

Basal cell carcinomas are the most common form of skin cancer. Tazarotene is a retinoic acid receptor selective retinoid that upregulates a tumor suppressor, tazarotene-induced gene 3 (TIG-3), in keratinocytes and psoriasis. Expression of TIG-3 in basal cell carcinomas was studied in an opened-label pilot biomarker study of 22 patients with basal cell carcinomas who applied tazarotene 0.1% gel for up to 12 wk prior to excision. Nineteen paired baseline and treated specimens were compared using immunohistochemistry and in situ hybridization. Compared to overlying normal epidermis, TIG-3 protein and mRNA were decreased in 14 and 18 of 19 basal cell carcinomas (74% and 95%), respectively (p < 0.001). Tazarotene treatment was associated with increased TIG-3 protein and mRNA expression in basal cell carcinomas compared to baseline levels (p < or = 0.001 and p = 0.028, respectively). Sixty percent of basal cell carcinomas treated with tazarotene decreased in size by at least 25%. Ten of 19 lesions improved histologically, including three complete responses. There was a correlation between the increased expression of TIG-3 protein and histologic improvement (p = 0.020), suggesting that suppression of TIG-3 may underlie the development of basal cell carcinomas. This association suggests that reversal of TIG-3 expression may help to explain the mechanism of retinoid action in epidermal differentiation and chemoprevention.     

Sparingly-soluble narcotic zinc tannates cause protracted analgesia in rats

Pain thresholds were determined in rats by the titration foot shock technique for 5–8 days after a single injection of zinc tannate salts of heroin (HZT)—41.0 and 81.9 mg/kg as base, LAAM (LZT)—41.0 and 81.9 mg/kg; and hydromorphone (DZT)—39.9 and 79.8 mg/kg. These zinc salts were synthesized, analyzed, suspended in a slow-release vehicle (SRV), and injected subcutaneously. Body weight and pain threshold of each rat were determined at the same time each day. Serum levels of the hydrolyzed metabolites of heroin were measured periodically in rats which had received similar injections of HZT. Analysis of variance showed that all narcotic preparations, except for low dose HZT, led to a significant (α = 0.05) elevation of pain threshold above that of the SRV control at 24 hr. Pain thresholds were significantly elevated for 3 days after low dose LZT, 4 days after both doses of DZT and 5 days after high dose LZT. Hydrolyzed heroin metabolites were present in the serum for 7 days after a single injection; at that time no analgesia was evident. The mean body weight of HZT and SRV rats continued to increase, whereas the LZT and DZT groups initially tost weight. This study shows that a single injection of 3 narcotic zinc tannate preparations can induce long-lasting elevations in pain thresholds, but tolerance to the analgesia is evident within days.     

Immunoglobulin G avidity in the serodiagnosis of congenital rubella syndrome

The avidity of specific IgG was investigated in three infants with serologically verified congenital rubella infection. Two sera were taken from each infant: the first soon after birth and the second at the age of 23 to 31 months. Avidity of specific IgG was measured by a protein-denaturing enzyme immunoassay using urea as the elution factor, and avidity then determined by the end-point ratio (derived from antibody titration) and the avidity index methods. Rubella-specific IgM was present in the first sera of all patients, but not in the second sera. However, low avidity of specific IgG persisted in two children until age 23 to 31 months, as determined by the end-point ratio method. These data are in agreement with the findings of previous studies of avidity in congenital rubella, and show the usefulness of the protein-denaturing IgG-avidity assays employing the end-point ratio method for serological diagnosis of congenital rubella even after disappearance of specific IgM.     

Cytomegalovirus seropositivity is significantly associated with mycosis fungoides and Sézary syndrome

Although mycosis fungoides (MF) may arise through persistent antigen stimulation, cytomegalovirus (CMV) is not a known risk factor. To study the incidence of seropositivity to viral infections, we compared MF and Sézary Syndrome (SS) patients to healthy bone marrow donors and other historical control groups. Baseline screening serologies at baseline were performed on 116 biopsy-proven MF/SS patients at MD Anderson Cancer Center from 1992 to 2001 and on healthy bone marrow donors evaluated by the transplant service from 1988 to 2001. Antibodies to HTLV-I/II, HIV-1, EBV, and CMV were measured using standard enzyme-linked immunosorbent (ELISA) and membrane enzyme immunoassay (MEIA) assays. One hundred thirteen (97.4%) of all MF/SS patients had positive CMV IgG serologies at initial presentation. Early- and late-stage patients' seropositivity rates were significantly higher than healthy bone marrow donor controls (chi(2).05(df=1) = 71.79). By stage, 98.1% of early-stage MF patients (IA, IB, IIA; 52/53) and 96.8% of late-stage MF and SS patients (IIB-IVB; 61/63) were seropositive compared with healthy bone marrow donors whose seropositivity rate was 57.3% (757/1322). Because the rate of CMV seropositivity increases with age, a subset of cutaneous T-cell lymphoma (CTCL) patients 55 years or younger were compared to age-matched healthy donor controls; their seropositivity rate for CMV was also significantly higher (chi(2).05 05(df=1) = 20.4). EBV titers were positive by serology in 13 patients who were examined prospectively. CMV seropositivity is highly associated with MF and SS, even in the earliest stages of the disease, and is significantly higher than that of healthy and immunocompromised controls.     

Unreported alcohol use was common but did not impact hepatitis C cure in HIV‐infected persons who use drugs

We investigated the prevalence and impact of heavy alcohol use on the hepatitis C virus (HCV) care continuum amongst HIV/HCV co‐infected persons who use drugs. In the CHAMPS study, 144 HIV/HCV co‐infected persons were randomized to contingent cash incentives, peer mentors and usual care to evaluate the impact on HCV care. Alcohol use was ascertained using the 10‐item AUDIT (hazardous: male ≥8, female ≥4) and phosphatidylethanol (PEth) (heavy: ≥50 ng/mL), an alcohol biomarker. Log binomial regression was used to evaluate the association between heavy alcohol use and failure to initiate treatment and to achieve sustained virologic response (SVR). Of the 135 participants with PEth data, median age was 55 years, 59% were male, 92% were Black, 91% reported a history of drug use, and 97% were on antiretroviral therapy. Hazardous drinking was reported on AUDIT by 28% of participants, and 35% had heavy alcohol use by PEth. Of the 47 individuals with a PEth ≥50 ng/mL, 23 (49%) reported no or minimal alcohol use by AUDIT. HCV treatment was initiated in 103 of 135 participants, and SVR was achieved in 92%. PEth ≥50 ng/mL (Relative Risk [RR] 0.72, 95% CI 0.35‐1.48) was not significantly associated with failure to initiate HCV treatment or failure to achieve SVR (RR 0.85, 95% CI 0.46‐1.57).In conclusion, alcohol use was common and frequently not detected by self‐report. However, heavy alcohol use, even when measured objectively, was not associated with failure to initiate HCV treatment or to achieve cure.